Transaction overview
Infinity Behavioral Health Services, a portfolio company of Thompson Street Capital Partners based in Fort Lauderdale, Florida, acquired Hyperion Billing Solutions on July 17, 2015. The exact financial details of the transaction were not disclosed, but it aimed to bolster Infinity's revenue cycle management capabilities within the behavioral health sector.
Hyperion Billing Solutions is a provider of billing and revenue cycle services tailored for healthcare organizations, particularly those in the behavioral health field. This acquisition aligns with Infinity’s strategy to expand its service offerings and strengthen its position as a leading player in behavioral health revenue cycle management solutions.
Deal structure and financing
The specific equity-debt split for this transaction was not disclosed publicly. Similarly, no information was provided on whether any lead banks were involved or the terms of the deal such as lock-up periods or IPO optionality. There is also no indication that Hyperion retained a stake in Infinity following the acquisition. Given the lack of detailed financial data, it remains unclear how much leverage was used to fund this transaction.
Strategic context
Infinity Behavioral Health Services sought to enhance its revenue cycle management capabilities through the acquisition of Hyperion Billing Solutions. The deal allowed Infinity to expand its service portfolio and potentially access new markets within the behavioral health sector. By integrating Hyperion's billing and revenue cycle services, Infinity aimed to offer a more comprehensive solution set to its clients.
Hyperion’s decision to divest was likely driven by strategic alignment with Thompson Street Capital Partners' investment strategy in the healthcare space, where consolidating service providers can lead to greater operational efficiency and market reach. The acquisition provided Hyperion an exit opportunity while positioning Infinity for continued growth under private equity ownership.
Regulatory path
No specific regulatory approvals or filings were mentioned for this transaction. Given the nature of the deal and its participants being based in the United States, it is likely that standard U.S. antitrust review procedures would have been followed by the Federal Trade Commission (FTC) or the Antitrust Division of the Department of Justice (DOJ). However, no specific regulatory timeline or remedies are documented publicly for this acquisition.